From the publishers of JADPRO

Multiple Myeloma Resource Center

Advertisement

Cancers (Basel)

Bispecific antibodies in multiple myeloma: Opportunities to enhance efficacy and improve safety

ASCO Daily News

Bispecific antibodies in refractory multiple myeloma: Basics and unanswered questions

Current Oncology

Relapsed/refractory multiple myeloma: A review of available therapies and clinical scenarios encountered in myeloma relapse

U.S. Food & Drug Administration

FDA grants accelerated approval to elranatamab-bcmm for multiple myeloma

Leukemia and Lymphoma

Health disparities experienced by Black and Hispanic Americans with multiple myeloma in the United States: A population-based study

Blood Cancer Journal

Black patients with multiple myeloma have better survival than white patients when treated equally: a matched cohort study

PR Newswire

U.S. FDA approves TALVEY™ (talquetamab-tgvs), a first-in-class bispecific therapy for the treatment of patients with heavily pretreated multiple myeloma

Blood

Final results from the first-in-human phase 1/2 study of modakafusp alfa, an immune-targeting attenuated cytokine, in patients (Pts) with relapsed/refractory multiple myeloma (RRMM)

ASCO 2023

First results from the RedirecTT-1 study with teclistamab (tec) + talquetamab (tal) simultaneously targeting BCMA and GPRC5D in patients (pts) with relapsed/refractory multiple myeloma (RRMM)

Blood

Increased COVID-19 breakthrough infection risk after SARS-CoV-2 vaccine boosting in patients with plasma cell disorders: A large nationwide Veterans Affairs study

The Lancet

SLiM CRAB criteria revisited: temporal trends in prognosis of patients with smoldering multiple myeloma who meet the definition of ‘biomarker-defined early multiple myeloma’—a systematic review with meta-analysis

Clinical Journal of Oncology Nursing

Steroid-associated side effects: A symptom management update on multiple myeloma treatment

Nature

Dietary and microbiome evidence in multiple myeloma and other plasma cell disorders

Transplantation and Cellular Therapy

Ethical challenges in CAR-T slot allocations

Transplantation and Cellular Therapy

Patient-reported outcomes in long-term survivors of autologous hematopoietic cell transplantation in multiple myeloma

Early Relapsed Multiple Myeloma With Translocation (11;14)

Treatment of Relapsed Multiple Myeloma With Bispecific Antibodies